Neupro
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $37.77 | 1 | 1 |
| 2023 | $12.72 | 2 | 2 |
| 2022 | $3,274 | 166 | 139 |
| 2021 | $55,485 | 3,023 | 974 |
| 2020 | $171,595 | 2,009 | 723 |
| 2019 | $240,368 | 3,748 | 1,077 |
| 2018 | $283,821 | 3,779 | 1,153 |
| 2017 | $426,365 | 5,098 | 1,597 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $534,755 | 450 | 45.3% |
| Food and Beverage | $323,914 | 17,028 | 27.4% |
| Consulting Fee | $235,081 | 32 | 19.9% |
| Travel and Lodging | $36,913 | 291 | 3.1% |
| Space rental or facility fees (teaching hospital only) | $33,250 | 16 | 2.8% |
| Unspecified | $17,044 | 8 | 1.4% |
| Education | $1.74 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 | UCB Biosciences Inc. | $7,116 | 0 |
| A MULTICENTER, OPEN LABEL, TWO-ARM STUDY TO EVALUATE THE IMPACT OF USING WEARABLE DEVICES IN ADDITION TO STANDARD CLINICAL PRACTICE ON PARKINSON'S SUBJECT SYMPTOMS MANAGEMENT - PHASE 4 | UCB SA | $5,323 | 1 |
| Patient and physician perceptions of disease management in Parkinsons disease - Results from a US-based multicenter survey | UCB, Inc. | $4,600 | 2 |
| A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects with Moderate to Severe Idiopathic Restless Legs Syndrome (RL0003) | UCB Biosciences Inc. | $5.00 | 0 |
Top Doctors Receiving Payments for Neupro — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Neurology | Orlando, FL | $457.59 | 25 |
| , M.D | Neurology | Fairfax, VA | $456.86 | 19 |
| , M.D | Neurology | Mesa, AZ | $456.26 | 29 |
| , MD | Neurology | Sarasota, FL | $453.27 | 27 |
| , M.D | Neurology | Canton, GA | $450.34 | 24 |
| , MD | Neurology | Denton, TX | $448.82 | 20 |
| , M.D | Dermatology | Garden City, NY | $448.45 | 5 |
| , MD | Neurology | Maple Shade, NJ | $447.73 | 31 |
| , MD | Neurology | Austin, TX | $446.76 | 25 |
| , M.D | Neurology | Stony Brook, NY | $442.78 | 6 |
| , M.D | Neurology | Lumberton, NC | $440.70 | 28 |
| , M.D | Specialist | Phoenix, AZ | $437.27 | 41 |
| , M.D | Specialist | Woodstock, GA | $434.22 | 17 |
| , M.D., PH.D | Neurology | Alexandria, VA | $433.61 | 34 |
| , M.D | Health | Winston-Salem, NC | $432.10 | 26 |
| , D.O | Neurology | Drexel Hill, PA | $428.00 | 21 |
| , MD | Neurology | South Miami, FL | $427.56 | 44 |
| , MD | Neurology | Crest Hill, IL | $425.54 | 18 |
| , MD | Student in an Organized Health Care Education/Training Program | Birmingham, AL | $424.72 | 21 |
| , MD | Neurology | Stanford, CA | $422.85 | 18 |
| Stephen Vanna | — | Maple Shade, NJ | $417.63 | 29 |
| Anthony Stephens | — | Crest Hill, IL | $414.31 | 27 |
| , M.D | Neurology | Cumming, GA | $413.22 | 23 |
| , M.D | Neurology | Goodyear, AZ | $412.97 | 31 |
| , MD | Neurology | Fort Payne, AL | $409.72 | 21 |
Manufacturing Companies
- UCB, Inc. $1.0M
- UCB SA $137,141
- UCB Biosciences Inc. $7,121
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 2,956
- Transactions 17,826
About Neupro
Neupro is a drug associated with $1.2M in payments to 2,956 healthcare providers, recorded across 17,826 transactions in the CMS Open Payments database. The primary manufacturer is UCB, Inc..
Payment data is available from 2017 to 2024. In 2024, $37.77 was paid across 1 transactions to 1 doctors.
The most common payment nature for Neupro is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($534,755, 45.3% of total).
Neupro is associated with 4 research studies, including "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495" ($7,116).